CAPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
CAPRICOR THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$6.65−0.06 (-0.89%)
Close on Oct 19, 2026
- Market cap
- $385.21M
- P/E (TTM)
- –
- Dividend yield
- –
Capricor Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Capricor Therapeutics | Industry median |
|---|---|---|
| Market Cap | $386.62M | $173.56M |
| Enterprise Value | $148.69M | $89.47M |
| PB Ratio | 1.57 | 2.04 |
| P/TBV Ratio | 1.57 | 2.34 |
Income (trailing twelve months)
| Measure | Capricor Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$135.16M | -$21.44M |
| Net Income | -$129.42M | -$22.46M |
| EBITDA | -$133.07M | -$16.91M |
| EPS (Diluted) | -$2.45 | -$0.83 |
Returns
| Measure | Capricor Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -73.7% | -53.1% |
| Return on Assets (ROA) | -51.5% | -41.0% |
| Return on Capital Employed (ROCE) | -40.3% | -37.8% |
Balance sheet
| Measure | Capricor Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $237.94M | $62.42M |
| Net Cash (Debt) | $237.94M | $15.68M |
| Net Cash Per Share | $4.09 | $0.66 |
| Equity (Book Value) | $246.22M | $48.79M |
| Book Value Per Share | $4.24 | $1.36 |
| Tangible Book Value | $246.22M | $23.06M |
| Working Capital | $209.17M | $75.77M |
Financial position
| Measure | Capricor Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 7.35 | 3.30 |
| Quick Ratio | 7.22 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Capricor Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$104.00M | -$12.35M |
| Capital Expenditures | -$10.91M | -$1.06M |
| Free Cash Flow | -$114.90M | -$20.28M |
| FCF Per Share | -$1.98 | -$0.42 |
Efficiency
| Measure | Capricor Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$560.25K | -$703.34K |
| Employee Count | 231 | 74 |
Dividends and yields
| Measure | Capricor Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -33.5% | -22.3% |
| FCF Yield | -29.7% | -8.62% |
Shares
| Measure | Capricor Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 58,139,000 | 58,227,550 |
| Shares Change (YoY) | 24.2% | 11.1% |
| Shares Change (QoQ) | 0.77% | 0.54% |
| Float | 57,222,900 | 49,230,300 |
| Shares Held by Insiders | 1.58% | 11.5% |
| Shares Held by Institutions | 67.6% | 59.4% |
Scores
| Measure | Capricor Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -0.08 | -0.17 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Capricor Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.